STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.

Manoj ChelvanambiRonald J FecekJennifer L TaylorWalter J Storkus

Published in: Journal for immunotherapy of cancer (2022)

Our data support the premise that i.t. delivery of low-dose STING agonist promotes VN and a proinflammatory TME supportive of TLS formation, enrichment in the TIL repertoire and tumor growth control.

Keyphrases

low dose
stem cells
high dose
skin cancer